Expert Analysis

Metabolic Complications and Adverse Events of HIV and Antiretroviral Therapy

Source: CCO Independent Conference Coverage of the 2007 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Metabolic Complications and Adverse Events of HIV and Antiretroviral Therapy

Faculty:

Judith S. Currier, MD, MSc
Sally Hodder, MD
Donald P. Kotler, MD

CME CREDIT INFORMATION

Release Date: 05/15/07

Expiration Date: 05/14/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.2 Nursing CE credits

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the metabolic results of the AIDS Clinical Trials Group 5142 study
Describe dietary fat intake of HIV-infected patients
List results of a trial of alendronate in patients with osteopenia

Topics covered include:

Dietary Fat Intake and Serum Lipid Levels in HIV-Infected Patients Receiving HAART
Lipid-Lowering Therapy in HIV-Infected and HIV-Negative Patients With Dyslipidemia
Administration of Lipid-Lowering Therapy Following Cardiovascular Events in HIV-Infected patients
Ezetimibe as Lipid-Lowering Therapy in HIV-Infected Patients Receiving HAART
Drug Interactions Between Lopinavir/Ritonavir and Rosuvastatin
Incidence of Hospitalization for MI in HIV-Infected and HIV-Negative Patients
Cardiovascular Events With Intermittent or Continuous Antiretroviral Therapy in HIV-Infected Patients: SMART
Evaluation of Cardiovascular Risk in HIV-Infected Patients Using Carotid Intima-Media Thickness: SUN
Lipoatrophy in HIV-Infected Patients Receiving NRTI, PI, and NNRTI-Sparing Treatment: ACTG 5142
TH9507: Effect of Growth Hormone–Releasing Factor Analogue on Visceral Adipose Tissue
Leptin Effects on Body Composition and Insulin Sensitivity in HIV-Infected Men With Hypoleptinemia
Stavudine Effects on Muscle Mitochondrial Activity and Insulin Resistance in Healthy Adults
Effects of Atazanavir/Ritonavir vs Saquinavir/Ritonavir With Tenofovir/Emtricitabine on Glucose Metabolism in HIV-Infected Patients
Incidence of End-Stage Renal Disease in Black HIV-Infected Patients Over Time
Renal Function in Black HIV-Infected Patients Receiving Tenofovir vs Nontenofovir-Containing Regimens
Renal Function in Patients With HIV
Prevalence and Mechanisms of Bone Disease in HIV-Infected Patients
ACTG 5163: Alendronate Treatment of Low Bone Mineral Density

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.